Investigational drug · Phase 2
NP137
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Endometrial Carcinoma, Cervix Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "NP137"
First trial start
2020
Dec 14, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NP137", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometrial Carcinoma
- Cervix Carcinoma
Approved drugs for the same conditions: Endometrial cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NP137" as an intervention, largest first.
- GYNecological Cancers Treated With NETrin mAbs in Combination With Chemotherapy and /or PembrolizumabPivotal-lookingCompleted
NETRIS PharmaIndustry
NCT04652076 · 238 participants · Start Dec 14, 2020 · Primary completion Oct 30, 2025
Drug: NP137; Pembrolizumab and 2 more · For: Endometrial Carcinoma; Cervix Carcinoma
Sites: Besançon, France; Bordeaux, France; Caen, France · 15 sites in all
Centre Leon BerardAcademic, hospital or other
NCT02977195 · 70 participants · Start Jan 9, 2017 · Primary completion Dec 2021
Drug: NP137 DL and RP2D · For: Advanced Solid Tumor; Endometrial Carcinoma; Hormone Receptor Positive
Sites: Lyon, France; Nantes, France; Toulouse, France
- NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 ImmunotherapiesActive, not recruiting
Centre Leon BerardAcademic, hospital or other
NCT05605496 · 57 participants · Start Jan 6, 2023 · Primary completion Jan 1, 2027
Drug: NP137; anti-PD-1/PD-L1 · For: Advanced Solid Tumors; Metastatic Solid Tumors
Sites: Lyon, France; Nice, France; Paris, France · 5 sites in all
- Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCCActive, not recruiting
University Hospital, GrenobleAcademic, hospital or other
NCT05546879 · 43 participants · Start Mar 15, 2023 · Primary completion Mar 19, 2026
Drug: NP137; Atezolizumab and 1 more · For: Hepatocellular Carcinoma
Sites: Grenoble, France; Angers, France; Bordeaux, France · 9 sites in all
University Hospital, GrenobleAcademic, hospital or other
NCT05546853 · 43 participants · Start Mar 28, 2023 · Primary completion Dec 9, 2024
Drug: NP137; Oxaliplatin and 3 more · For: Pancreatic Ductal Adenocarcinoma
Sites: Grenoble, France; Bordeaux, France; Lille, France · 9 sites in all
Aram HezelAcademic, hospital or other
NCT06203821 · 25 participants (planned) · Start Sep 1, 2026 · Primary completion May 30, 2027
Drug: NP137 · For: Pancreatic Cancer
Sites: Rochester, New York
- Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]Terminated
Centre Leon BerardAcademic, hospital or other
NCT06150040 · 1 participants · Start Sep 11, 2024 · Primary completion Feb 18, 2025
Drug: NP137; Azacitidine Injection and 1 more · For: Acute Myeloid Leukemia Refractory
Sites: Lyon, France
Newest research
PubMed records naming it or its code names, newest first.
- Mechanistic insights into NET1-UNC5B complex formation and Its targeted disruption by NP137 fab and NET1 peptide competitors.
Rafiei F, Gupta M, Kitova EN, et al. · Nat Commun 2026
- A self-amplifying nerve-fibroblast circuit drives colorectal cancer progression.
Kobayashi H, Iida T, Ochiai Y, et al. · Cancer Cell 2026
- Netrin1 blockade alleviates resistance to chemotherapy in pancreatic cancer.
Roth G, Artru P, Bouche O, et al. · Nature 2026
- Netrin-DCC inhibition suppresses neuroendocrine neoplasm growth in vivo.
Sela Peremen L, Telerman A, Kahan Yossef Y, et al. · Endocr Relat Cancer 2025
- Sonic hedgehog medulloblastomas are dependent on Netrin-1 for survival.
Talbot J, Fombonne J, Torrejon J, et al. · Nat Commun 2025
- Anti-Netrin-1 decorated nanoparticles combined with chemotherapy for the treatment of triple-negative breast cancer.
Breusa S, Thomas E, Baldinotti N, et al. · Biomater Adv 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.